Progesteronantagonist cdb-4124 bei der behandlung von brustkrebs

Progesteron antagonist cdb-4124 in the treatment of breast cancer

Antagonist de progestérone cdb-4124 dans le traitement du cancer du sein

Abstract

The subject matter of the instant invention is pertinent to the field of cancer treatment. In particular, the instant invention is relevant to the treatment and/or prevention of breast cancer in a patient. Compositions for practicing the methods, comprising selective progesterone receptor modulators, which function as progesterone agonists in the uterus and as progesterone antagonists in the breast tissue and exhibit only low affinity for glucocorticoid and estrogen receptors, are also disclosed. Embodiments of the instant invention also disclose methods for preventing the development of breast cancer in patients undergoing hormone replacement therapy or estrogen therapy.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (65)

    Publication numberPublication dateAssigneeTitle
    US-6509334-B1January 21, 2003American Home Products Corporation, Ligand Pharmaceuticals, Inc.Cyclocarbamate derivatives as progesterone receptor modulators
    US-5095129-AMarch 10, 1992Schering Aktiengesellschaft19,11 β-bridged steroids, their manufacture and pharmaceutical preparations containing them
    US-4508703-AApril 02, 1985Parfums Christian DiorProduction of pulverulent mixtures of lipidic and hydrophobic constituents
    US-6441019-B2August 27, 2002Wyeth, Ligand Pharmaceuticals, Inc.Cyclocarbamate and cyclic amide derivatives
    US-6417214-B1July 09, 2002Wyeth, Ligand Pharmaceuticals, Inc.3,3-substituted indoline derivatives
    US-5843931-ADecember 01, 1998Shering Aktiengesellschaft6,7-modified 11β-aryl-4-oestrenes
    US-6713478-B2March 30, 2004Wyeth, Ligand Pharmaceuticals, Inc.Cyclocarbamate derivatives as progesterone receptor modulators
    WO-0174840-A2October 11, 2001The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregna 21-substituted 19-norpregnadienedione as antiprogestational agents
    US-4386085-AMay 31, 1983Roussell UclafNovel steroids
    US-5232915-AAugust 03, 1993Schering Aktiengesellschaft9α-hydroxy-19,11β-bridged steroids, their production and pharmaceutical preparations containing these steroids
    WO-9824803-A1June 11, 1998Schering AktiengesellschaftEsters steroides, leur procede de preparation et leur utilisation pharmaceutique
    US-5077211-ADecember 31, 1991Applied Genetics, Inc.Purification and administration of dna repair enzymes
    US-4447424-AMay 08, 1984Roussel UclafSteroid derivatives
    US-5693646-ADecember 02, 1997Ligand Pharmaceuticals IncorporatedSteroid receptor modulator compounds and methods
    US-6391907-B1May 21, 2002American Home Products Corporation, Ligand Pharmaceuticals, Inc.Indoline derivatives
    US-5688808-ANovember 18, 1997Ligand Pharmaceuticals IncorporatedSteroid receptor modulator compounds and methods
    EP-0289073-A1November 02, 1988Akzo N.V.Dérivés de 11-arylestranes et 11-arylprégnanes
    US-4921845-AMay 01, 1990Akzo N.V.11-arylsteroid compounds
    US-5576310-ANovember 19, 1996Jenapharm Gmbh11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
    WO-2007103510-A2September 13, 2007Danco Laboratories LlcMethods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
    US-4780461-AOctober 25, 1988Schering Aktiengesellschaft13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
    US-5273971-ADecember 28, 1993Schering Aktiengesellschaft13-alkyl-11β-phenylgonanes
    US-5439913-AAugust 08, 1995Schering AktiengesellschaftContraception method using competitive progesterone antagonists and novel compounds useful therein
    US-4609651-ASeptember 02, 1986Schering Aktiengesellschaft11β-arylestradienes, their production, and pharmaceutical preparations containing same
    DE-19652408-A1June 10, 1998Schering AgSteroidester, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
    US-5739125-AApril 14, 1998Schering Aktiengesellschaft11 Beta-aryl-gona-4, 9-dien-3-ones
    US-6306851-B1October 23, 2001American Home Products Corporation, Ligand Pharmaceuticals, Inc.Cyclocarbamate and cyclic amide derivatives
    US-5693628-ADecember 02, 1997Jenapharm Gmbh11-benzaldoxime-estra-diene derivatives, methods for their production and pharmaceuticals containing these compounds
    US-5292878-AMarch 08, 1994Akzo N.V.17-spirofuran-3'-ylidene steroids
    US-6358948-B1March 19, 2002American Home Products Corporation, Ligand Pharmaceuticals, Inc.Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
    US-4519946-AMay 28, 1985Roussel UclafSteroids
    US-4871724-AOctober 03, 1989Akzo N.V.Novel 11-aryloestrane and 11-arylpregnane derivatives
    US-5407928-AApril 18, 1995Schering Aktiengesellschaft11β-aryl-gona-4,9-dien-3-ones
    WO-9834947-A1August 13, 1998Schering AktiengesellschaftANTIGESTAGENIC STEROIDS WITH A FLUORINATED 17α-ALKYL CHAIN
    US-6861415-B2March 01, 2005The United States Of America As Represented By The Department Of Health And Human Services21-substituted progesterone derivatives as new antiprogestational agents
    US-5693647-ADecember 02, 1997Ligand Pharmaceuticals IncorporatedSteroid receptor modulator compounds and methods
    US-4829060-AMay 09, 1989Schering Aktiengesellschaft11 Beta-N,N-dimethylaminophenyl-estradienes, their manufacture and pharmaceutical preparations containing them
    US-6380235-B1April 30, 2002American Home Products Corporation, Ligand Pharmaceuticals, Inc.Benzimidazolones and analogues
    US-4621023-ANovember 04, 1986Parfums Christian DiorMethod of homogenizing dispersions of hydrated lipidic lamellar phases and suspensions obtained by the said method
    US-5446178-AAugust 29, 1995Schering AktiengesellschaftProcess for preparing 19,11β-bridged steroids
    US-5089488-AFebruary 18, 1992Schering Aktiengesellschaftβ-(4-isopropenylphenyl)estra-4,9-dienes, their production, and pharmaceutical preparations containing same
    US-6369056-B1April 09, 2002American Home Products Corporation, Ligand Pharmaceuticals, Inc.Cyclic urea and cyclic amide derivatives
    US-5728689-AMarch 17, 1998Schering Aktiengesellschaft11β-aryl-4-estrenes, process for their production as well as their use as pharmaceutical agents
    US-6566358-B2May 20, 2003Wyeth, Ligand Pharmaceuticals, Inc.Cyclocarbamate derivatives as progesterone receptor modulators
    US-5696133-ADecember 09, 1997Ligand Pharmaceuticals IncorporatedSteroid receptor modulator compounds and methods
    US-5843933-ADecember 01, 1998Schering Aktiengesellschaft11β-aryl-4-estrenes, process for their production as well as their use as pharmaceutical agents
    DE-4332284-A1March 23, 1995Jenapharm GmbhNeue 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
    US-5696130-ADecember 09, 1997Ligand Pharmaceuticals IncorporatedTricyclic steroid receptor modulator compounds and methods
    US-5446036-AAugust 29, 1995Schering Aktiengesellschaft13-alkyl-11beta-phenylgonanes
    US-6900193-B1May 31, 2005The United States Of America As Represented By The Department Of Health And Human ServicesStructural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
    US-5244886-ASeptember 14, 1993Schering Aktiengesellschaft11β-phenyl-14βH steroids
    US-6339098-B1January 15, 2002American Home Products Corporation, Ligand Pharmaceuticals, Inc.2,1-benzisothiazoline 2,2-dioxides
    WO-9741145-A1November 06, 1997The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human ServicesDerives de progesterone substitues 21 pouvant etre utilises comme nouveaux agents antiprogestatifs
    WO-9945023-A1September 10, 1999Jenapharm Gmbh & Co. KgS-SUBSTITUIERTE 11β-BENZALDOXIM-ESTRA-4,9-DIEN-KOHLENSÄURETHIOLESTER, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE VERBINDUNGEN ENTHALTENE PHARMAZEUTISCHE ZUBEREITUNGEN
    US-5478956-ADecember 26, 1995Schering Aktiengesellschaft8-En-19 11 β-bridged steroids, their production and pharmaceutical preparations containing them
    US-5753655-AMay 19, 1998Ortho Pharmaceutical Corporation1-arylsulphonyl, arylcarbonyl and arylthiocarbonyl pyridazino derivatives and methods of preparation
    US-5684151-ANovember 04, 1997Ortho Pharmaceutical Corporation1-arylsulphonyl, arylcarbonyl and 1-arylphosphonyl-3-phenyl-1,4,5,6-tetrahydropyridazines
    US-4634695-AJanuary 06, 1987Roussel UclafSteroid derivatives
    US-5093507-AMarch 03, 1992Schering Aktiengesellschaft10β,11β-bridged steroids
    US-5696127-ADecember 09, 1997Ligand Pharmaceuticals IncorporatedSteroid receptor modulator compounds and methods
    DE-4216004-A1November 18, 1993Schering AgUse of competitive progesterone antagonists - to inhibit development of endometrial glands essential for implantation of eggs in the uterus
    DE-4434488-A1March 21, 1996Schering AgSteroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
    DE-4216003-A1November 18, 1993Schering AgDissoziierte kompetitive Progesteronantagonisten
    DE-4332283-A1April 13, 1995Jenapharm GmbhNeue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
    US-4814327-AMarch 21, 1989Schering Aktiengesellschaft11 β-(4-isopropenylphenyl)estra-4,9-dienes, their production, and pharmaceutical preparations containing same

NO-Patent Citations (17)

    Title
    "The Merck Index", 2001, MERCK & CO.
    ALLAN ET AL., STEROIDS, vol. 71, 2006, pages 949 - 954
    ATTARDI ET AL., MOL. CELL. ENDOCRIN., vol. 188, 2002, pages 111 - 123
    BAUERFEIND I ET AL: "Endocrine agents in the treatment of advanced breast cancer", GYNAKOLOGE 199908 DE, vol. 32, no. 8, August 1999 (1999-08-01), pages 605 - 613, XP002533572, ISSN: 0017-5994
    BELAGNER ET AL., STEROIDS, vol. 37, 1981, pages 361 - 382
    JIANG ET AL., STEROIDS, vol. 71, 2006, pages 949 - 954
    KANG ET AL., BIOORG. MED. CHEM. LETT., vol. 15, 2007, pages 907 - 910
    KANG ET AL., BIOORG. MED. CHEM. LETT., vol. 17, 2007, pages 2531 - 2534
    LEO JOYCE C L ET AL: "The activities of progesterone receptor isoform A and B are differentially modulated by their ligands in a gene-selective manner.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 1 JAN 2008, vol. 122, no. 1, 1 January 2008 (2008-01-01), pages 230 - 243, XP002533284, ISSN: 1097-0215
    MEALY N E ET AL: "CDB-4124", DRUGS OF THE FUTURE 200411 ES, vol. 29, no. 11, November 2004 (2004-11-01), pages 1133, XP009118559, ISSN: 0377-8282
    MICHNA ET AL., J. STEROID BIOCHEM. MOLEC. BIOL., vol. 41, 1992, pages 339 - 348
    NABHOLTZ J M ET AL: "Anastrozole (Arimidex(TM)) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 39, no. 12, 1 August 2003 (2003-08-01), pages 1684 - 1689, XP004441204, ISSN: 0959-8049
    ROSE C ET AL: "An open randomised trial of second-line endocrine therapy in advanced breast cancer - comparison of the aromatase inhibitors letrozole and anastrozole", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 39, no. 16, 1 November 2003 (2003-11-01), pages 2318 - 2327, XP004461007, ISSN: 0959-8049
    STRATTON ET AL., HU. REPROD., vol. 15, 2000, pages 1092 - 1099
    T. W. GREENE; P. G. M. WUTZ: "Protective Groups in Organic Synthesis", 1991, WILEY-INTERSCIENCE
    WIEHLE RONALD D ET AL: "Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestin.", ONCOLOGY REPORTS JUL 2007, vol. 18, no. 1, July 2007 (2007-07-01), pages 167 - 174, XP009118560, ISSN: 1021-335X
    ZHI ET AL., J. MED. CHEM., vol. 41, 1998, pages 291 - 302

Cited By (0)

    Publication numberPublication dateAssigneeTitle